Development Strategy
Innovation Driven,BioCity has established a rich and potential Best-in-Class pipelines targeting therapeutic areas including oncology and Nephropathy.
As a fast-growing clinical-stage biopharmaceutical company with core competitiveness from project establishment to translational medicine and clinical development ,
BioCity is willing to collaborate with its partners to provide patients
with new therapeutic drugs and improve their quality of life.
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China